En las noticias
Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.
Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
A combination of the next-generation immunotherapies botensilimab and balstilimab showed clinical activity in treating patients with refractory metastatic microsatellite-stable (MSS) colorectal cancer, according to new findings presented by El-Khoueiry et al at the 2023 ASCO Gastrointestinal Cancers Symposium (Abstract LBA8).
Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
Fifteen months after the FDA blindsided Agenus with a decision not to offer accelerated approval for the cervical cancer drug balstilimab, the biotech is back with fresh data for a combo featuring the therapy it claims could finally make headway.
Immunotherapy with two novel drugs shows activity in colorectal cancer
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.
3 Forbes Road
Lexington, Massachusetts 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200